Brensocatib is an oral anti-inflammatory agent and a potent inhibitor of dipeptidyl peptidase-1 (DPP-1), developed for the treatment of non-cystic fibrosis bronchiectasis to reduce airway inflammation… Read more

![Chemical structure of (R)-N-((R)-1-Cyano-2-(4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-1,4-oxazepane-2-carboxamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2758816-16-7-R-N-R-1-Cyano-2-4-3-methyl-2-oxo-23-dihydrobenzodoxazol-5-ylphenylethyl-14-oxazepane-2-carboxamide.png&w=3840&q=75)
![Chemical structure of (R)-N-((S)-1-Cyano-2-(4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-1,4-oxazepane-2-carboxamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2758816-15-6-R-N-S-1-Cyano-2-4-3-methyl-2-oxo-23-dihydrobenzodoxazol-5-ylphenylethyl-14-oxazepane-2-carboxamide.png&w=3840&q=75)







![Chemical structure of (S)-N-((R)-1-Cyano-2-(4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-1,4-oxazepane-2-carboxamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2758816-13-4-S-N-R-1-Cyano-2-4-3-methyl-2-oxo-23-dihydrobenzodoxazol-5-ylphenylethyl-14-oxazepane-2-carboxamide.png&w=3840&q=75)


![Chemical structure of 5-(5,5-Dimethyl-1,3,2-dioxaborinan-2-yl)benzo[d]oxazol-2(3H)-one](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F5-55-Dimethyl-132-dioxaborinan-2-ylbenzodoxazol-23H-one.png&w=3840&q=75)
![Chemical structure of 5-Chloro-3-methylbenzo[d]oxazol-2(3H)-one](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F5790-90-9-5-Chloro-3-methylbenzodoxazol-23H-one.png&w=3840&q=75)
![Chemical structure of [5,5'-Bibenzo[d]oxazole]-2,2'(3H,3'H)-dione](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F206430-84-4-55-Bibenzodoxazole-223H3H-dione.png&w=3840&q=75)













Brensocatib is an oral anti-inflammatory agent and a potent inhibitor of dipeptidyl peptidase-1 (DPP-1), developed for the treatment of non-cystic fibrosis bronchiectasis to reduce airway inflammation and associated lung damage. Within this category, pharmaceutical laboratories can access high-quality reference standards for Brensocatib, alongside a range of critical related compounds essential for rigorous quality control and method validation. These include identified process-related impurities, such as specific N-nitroso derivatives and oxazepane-based intermediates, as well as synthetic precursors. Additionally, stable isotope labelled compounds are available to serve as internal standards in mass spectrometry-based bioanalytical assays, facilitating accurate pharmacokinetic studies and precise impurity profiling. Utilizing these comprehensive reference materials ensures consistent and reliable analytical testing throughout the drug development lifecycle, supporting compliance with regulatory standards for purity and safety.